Vanderbilt Center for Immunobiology Archives

Alyssa Hasty, PhD, left, Jeffrey Rathmell, PhD, and Kamran Idrees, MD, MSCI, are part of a multidisciplinary team that received a 2023 Endeavor Award from The Mark Foundation for Cancer Research to study the connection between obesity and cancer. Team members not pictured include Kathryn Wellen, PhD, Liza Makowski, PhD, and Kathryn Beckermann, MD, PhD.

Vanderbilt-led team receives 2023 Endeavor Award from The Mark Foundation for Cancer Research

Oct. 24, 2023—A multidisciplinary team of investigators has received a 2023 Endeavor Award from The Mark Foundation for Cancer Research to support four closely linked projects exploring the fundamental mechanisms that drive the obesity-cancer connection,

Jeffrey Rathmell, PhD, left, and Kelsey Voss, PhD, led a multidisciplinary team that identified iron metabolism in T cells as a potential target for treating lupus.

Study identifies potential new approach for treating lupus

Jan. 13, 2023—A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.

The study team included (front row, from left) Kelsey Voss, PhD, Rachel Bonami, PhD, Erin Wilfong, MD, PhD, (back row, from left) Jonathan Irish, PhD, Jeff Rathmell, PhD, and Ivelin Georgiev, PhD.

Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

Jul. 20, 2022—In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

Ayaka Sugiura and Jeff Rathmell, PhD, are studying a metabolic enzyme involved in T cell function that may offer a new target for anti-inflammatory therapeutics.

CRISPR screen identifies new anti-inflammatory drug target

Nov. 11, 2021—A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

From left, Kimryn Rathmell, MD, PhD, Bradley Reinfeld, Matthew Madden and Jeffrey Rathmell, PhD, have discovered that immune cells — not cancer cells — are the major glucose consumers in the tumor microenvironment, upending a century-old observation.

Study revises understanding of cancer metabolism

Apr. 7, 2021—Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

Probing innate immunity

May. 19, 2020—Manuel Ascano team validates an inhibitor of the cGAS-STING signaling pathway, which is important for cellular innate immunity against bacteria, viruses, and our own damaged DNA.

Rathmell lands award from Lupus Research Alliance

Oct. 31, 2019—Jeffrey Rathmell, PhD, is a 2019 recipient of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity.

Pua lands NIH Director’s New Innovator Award

Oct. 1, 2019—Heather Pua, MD, PhD, one of 60 investigators to receive the 2019 NIH Director’s New Innovator Award, will explore a novel type of cell signaling by RNAs in allergic airway inflammation.

Jeffrey Rathmell, PhD, directs the Vanderbilt Center for Immunobiology.

Center for Immunobiology grows, bolsters program

Jul. 18, 2019—The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.

New institute to focus on immune system

Jun. 29, 2017—Vanderbilt University Medical Center (VUMC) is launching a new institute to coordinate initiatives among the rapidly evolving disciplines of infection biology, immunology and inflammatory diseases.